BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Special Report

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

January 24, 2025 | News

Hyundai ADM Bio Showcases Innovative Oral Chemotherapy OTX-M at Biotech Showcase 2025

Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug O...

January 23, 2025 | News

Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...

January 22, 2025 | News

Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | News

China Approves Sarclisa-Pd for Relapsed Multiple Myeloma, Backed by Pivotal Trial and Real-World Data.

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa ...

January 13, 2025 | News

Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...

January 10, 2025 | News

2025 Pharma and Medical Device Trends for Manufacturing Leaders

2025 Pharma and Medical Device Trends for Manufacturing LeadersKey Insights for Regulated Manufacturing Today and Tomorrow In ...

January 07, 2025 | News

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctoco...

January 02, 2025 | News

25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare

The pharmaceutical industry is bracing for a transformative year as 2025 approaches, with 25 high-revenue drugs set to lose patent protection. These expira...

December 27, 2024 | Analysis

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Sanofi and Teva Report Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpo...

December 18, 2024 | News

Novo Holdings Completes Catalent Acquisition; Novo Nordisk Secures Strategic Manufacturing Sites

Analysis of Novo Holdings A/S’s Acquisition of Catalent and Novo Nordisk’s Strategic Expansion The imminent completion of ...

December 16, 2024 | Analysis

25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine

Biopharma in 2025: AI Transforming Drug Discovery and Precision Medicine The biopharma landscape in 2025 is poised for an unprecedented transformation, dr...

December 13, 2024 | Analysis

ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...

December 13, 2024 | News

Stay Connected